How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

Topics: Hematologic Malignancies • Medical Oncology • Lymphoma • NCI-CCC Tumor Board Question • CLL • Hematology • Cleveland Clinic • NCI-CCC Lymphoma Tumor Board Question

Related Questions